Open science collaboration reveals promising new coronavirus antiviral
A promising broad-spectrum coronavirus antiviral pre-clinical candidate, ASAP-0017445, has been discovered.
ASAP-0017445 is designed to be a direct-to-generic, globally accessible treatment ready for future coronavirus pandemics. The pre-clinical drug candidate, which exhibited encouraging preliminary safety and efficacy results, was recently nominated by Drugs for Neglected Diseases initiative (DNDi), a non-profit medical research organisation, as a highly effective antiviral for coronaviruses.
The drug was developed by the COVID Moonshot and ASAP (AI-driven Structure-enabled Antiviral Platform) Discovery Consortium, formed during the Covid-19 pandemic. The consortia aimed to accelerate open-science antiviral drug discovery and deliver oral antivirals to prevent future pandemics.
The structure of ASAP-0017445 was publicly disclosed in March 2025. The patent and all data generated during the compound’s development have recently been published to support the open science approach.
ASAP member Enamine delivered over 2,000 new compounds during the early stages of the programme, enabling rapid production of novel molecules, compound management, and logistics. The company also performed Tier 1 ADME tests in close proximity to the compound depository, essential in shortening Design-Make-Test-Analyse cycles.
“We are proud to have been a part of this groundbreaking open science collaboration, where researchers from across the world have come together to advance vital drug discovery efforts,” said Vladimir Ivanov, Executive Vice President of Enamine. “We are grateful to all the other organisations who played a part in contributing to the global effort to strengthen resilience against future pandemics.”
